Indonesia oligonucleotide synthesis market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

Indonesia Oligonucleotide Synthesis Market Overview

• The Indonesia Oligonucleotide Synthesis Market is valued at USD 160 million, based on a five-year historical analysis. This growth is primarily driven by advancements in biotechnology, increasing demand for personalized medicine, and the rising prevalence of genetic disorders. The market is also supported by the growing number of research initiatives and collaborations between academic institutions and pharmaceutical companies. Recent trends highlight the adoption of automated synthesis platforms, expansion of genomic research, and integration of oligonucleotide therapeutics into clinical pipelines, further accelerating market expansion .
• Key cities such as Jakarta, Bandung, and Surabaya continue to dominate the market due to their robust healthcare infrastructure, presence of research institutions, and pharmaceutical companies. Jakarta, being the capital, serves as a hub for biotechnology firms and research organizations, while Bandung and Surabaya contribute through their academic institutions and growing biotech sectors. The concentration of clinical laboratories, university research centers, and biotech startups in these cities drives regional demand for oligonucleotide synthesis services .
• In 2023, the Indonesian government implemented the “Regulation of the Minister of Health No. 28/2023 on Biotechnology Product Approval and Commercialization,” issued by the Ministry of Health. This regulation establishes a framework for the approval and commercialization of oligonucleotide-based therapies, including operational requirements for clinical trial data submission, product safety and efficacy standards, and licensing procedures for manufacturers and importers. The regulation streamlines the approval process, ensuring innovative therapies reach the market efficiently while maintaining rigorous safety and efficacy standards .

Indonesia Oligonucleotide Synthesis Market Segmentation

By Product Type:The product type segmentation includes Primers, Probes, Linkers & Adaptors, Custom Oligonucleotides, Reagents & Consumables, and Equipment. Among these, Custom Oligonucleotides lead the market due to their tailored applications in research and diagnostics, catering to specific customer needs. The demand for personalized solutions in genetic research and therapeutic applications drives this segment's growth, as researchers increasingly seek customized oligonucleotides for their projects. The segment’s dominance is reinforced by the growing use of gene editing and synthetic biology platforms in Indonesia .

By Application:The application segmentation encompasses PCR & qPCR, DNA & RNA Interference (RNAi), Therapeutics, Diagnostics, Research & Development, and Others. The PCR & qPCR segment remains the most dominant due to its widespread use in clinical diagnostics and research settings. The increasing focus on genetic testing, infectious disease detection, and molecular diagnostics has significantly boosted demand for PCR-related applications, making it a critical area of growth in the market. The rise in public health initiatives and infectious disease surveillance programs further supports this segment’s leadership .

Indonesia Oligonucleotide Synthesis Market Competitive Landscape

The Indonesia Oligonucleotide Synthesis Market is characterized by a dynamic mix of regional and international players. Leading participants such as Thermo Fisher Scientific Inc., Integrated DNA Technologies, Inc., Eurofins Genomics, Merck KGaA (Sigma-Aldrich), GenScript Biotech Corporation, Biosearch Technologies, Inc. (LGC Group), Twist Bioscience Corporation, Bioneer Corporation, ATDBio Ltd., LGC Biosearch Technologies, Oligo Factory, AITbiotech Pte Ltd., DNA Script, TriLink BioTechnologies, Nucleic Acid Solutions, PT Genetika Science Indonesia, PT Bio Farma (Persero), PT Prodia Stem Cell Indonesia contribute to innovation, geographic expansion, and service delivery in this space.

Indonesia Oligonucleotide Synthesis Market Industry Analysis

Growth Drivers

• Increasing Demand for Personalized Medicine:The Indonesian healthcare sector is witnessing a surge in personalized medicine, driven by a growing population of approximately 270 million. In future, the market for personalized medicine is projected to reach IDR 12 trillion, reflecting a 15% increase from the previous year. This demand is fueled by advancements in genomics and biotechnology, leading to a higher need for oligonucleotide synthesis in developing targeted therapies for various diseases, including cancer and genetic disorders.
• Growth in Biotechnology Research and Development:Indonesia's investment in biotechnology R&D is expected to exceed IDR 6 trillion in future, marking a 20% increase from the previous year. This growth is supported by government initiatives aimed at enhancing the country's research capabilities. The rise in biotechnology research directly correlates with the demand for oligonucleotide synthesis, as researchers require high-quality oligonucleotides for various applications, including drug development and genetic research.
• Rising Prevalence of Genetic Disorders:The prevalence of genetic disorders in Indonesia is estimated to affect around 1.7 million individuals annually. With a growing awareness of genetic testing and therapies, the demand for oligonucleotide synthesis is expected to rise significantly. In future, the government plans to allocate IDR 3 trillion for initiatives aimed at addressing genetic disorders, further driving the need for customized oligonucleotides in diagnostics and treatment solutions.

Market Challenges

• High Costs of Oligonucleotide Synthesis:The cost of oligonucleotide synthesis in Indonesia can range from IDR 1 million to IDR 6 million per synthesis, depending on the complexity and length of the oligonucleotide. This high cost poses a significant barrier for many research institutions and healthcare providers, limiting access to essential genetic research and personalized medicine solutions. As a result, many potential users may seek alternative, more affordable technologies.
• Limited Availability of Skilled Professionals:The oligonucleotide synthesis market in Indonesia faces a shortage of skilled professionals, with only about 2,500 qualified biotechnologists available in the workforce. This shortage hampers the growth of the industry, as the demand for expertise in oligonucleotide design and synthesis continues to rise. Educational institutions are struggling to keep pace with the industry's needs, leading to a skills gap that could hinder future advancements.

Indonesia Oligonucleotide Synthesis Market Future Outlook

The future of the oligonucleotide synthesis market in Indonesia appears promising, driven by technological advancements and increased investment in biotechnology. As the healthcare sector continues to embrace personalized medicine, the demand for high-quality oligonucleotides is expected to grow. Furthermore, collaborations between private companies and academic institutions will likely enhance research capabilities, fostering innovation. The integration of automation and AI in synthesis processes will also streamline production, making oligonucleotide synthesis more efficient and accessible to a broader range of users.

Market Opportunities

• Expansion of Applications in Diagnostics:The increasing focus on early disease detection presents a significant opportunity for oligonucleotide synthesis. With the Indonesian government investing IDR 2 trillion in diagnostic technologies in future, the demand for oligonucleotides in molecular diagnostics is expected to rise, enhancing the market's growth potential.
• Collaborations with Academic Institutions:Partnerships between biotechnology firms and academic institutions can drive innovation in oligonucleotide synthesis. With over 100 universities in Indonesia focusing on life sciences, collaborative research initiatives can lead to the development of novel applications, expanding the market's reach and fostering advancements in genetic research and therapies.